Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, Alberto Gil-Jimenez, Hayri E Balcioglu, Astrid A M Oostvogels, Maureen J B Aarts, Joost L Boormans, Paul Hamberg, Michiel S van der Heijden, Bernadett E Szabados, Geert J L H van Leenders, Niven Mehra, Jens Voortman, Hans M Westgeest, Ronald de Wit, Astrid A M van der Veldt, Reno Debets, Martijn P Lolkema
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, based on whole-genome DNA (n = 70) and RNA-sequencing (n = 41) of fresh metastatic biopsy samples, collected prior to treatment with pembrolizumab. We find that PD-L1 combined positivity score does not, whereas tumor mutational burden and APOBEC mutagenesis modestly predict response...
February 14, 2024: Nature Communications